A trusted leader in the renal community delivering unique products to people with kidney disease.
We are a fully integrated biopharmaceutical company. Our team works to address complications of kidney disease. We have both a commercially available medicine and a late stage oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), vadadustat, in global Phase 3 clinical development for the treatment of anemia due to CKD. Vadadustat and other HIF-PHIs are based on Nobel Prize-winning science.
Vadadustat is an investigational drug that has not been approved by the U.S. Food and Drug Administration (FDA) or any regulatory authority for use outside of Japan. Within Japan, Vadadustat, which completed its global Phase 3 program for the treatment of anemia due to CKD in both dialysis-dependent and non-dialysis dependent adult patients, and will be marketed by Mitsubishi Tanabe Pharma Corporation in Japan under the trade name VAFSEO™.
Be part of a passionate team working to protect the kidneys and to innovate for better lives
Nearly 37 million Americans
are currently affected by chronic kidney disease.
Chronic kidney disease is a serious and life-altering illness that is persistent, progressive, and irreversible.
Centers for Disease Control and Prevention. Chronic Kidney Disease in the United States, 2019. Available at: https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html. Accessed: September 3, 2019.
BC-0014 12/20
Akebia Therapeutics, Inc.
245 First Street, Suite 1400
Cambridge, MA 02142
+1 617.871.2098 phone
+1 617.871.2099 fax